Intensive Lipid-Lowering Therapy for Patients With Aortic Stenosis

American Journal of Cardiology

Volumn 102, Issue 11, 2008, Pages 1571-1576

  Pedersen, Terje R ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; EZETIMIBE; FLUINDOSTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; SIMVASTATIN;

AORTA STENOSIS; CLINICAL RESEARCH; CLINICAL TRIAL; FOLLOW UP; HUMAN; HYPERLIPIDEMIA; LIPOPROTEIN BLOOD LEVEL; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING;

EID: 56349142228     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2008.07.028     Document Type: Review

References (25)

1. Bonow R.O., Carabello B.A., Kanu C., de Leon Jr. A.C., Faxon D.P., Freed M.D., Gaasch W.H., Lytle B.W., Nishimura R.A., O'Gara P.T., et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation 114 (2006) e84-e231
2. Aronow W.S. Valvular aortic stenosis in the elderly. Cardiol Rev 15 (2007) 217-225
3. Novaro G.M., Tiong I.Y., Pearce G.L., Lauer M.S., Sprecher D.L., and Griffin B.P. Effect of hydroxymethylglutaryl coenzyme A reductase inhibitors on the progression of calcific aortic stenosis. Circulation 104 (2001) 2205-2209
4. Moura L.M., Ramos S.F., Zamorano J.L., Barros I.M., Azevedo L.F., Rocha-Goncalves F., and Rajamannan N.M. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol 49 (2007) 554-561
5. Cowell S.J., Newby D.E., Prescott R.J., Bloomfield P., Reid J., Northridge D.B., and Boon N.A. Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression (SALTIRE) Investigators. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 352 (2005) 2389-2397
6. Chan K.L., Teo K., Tam J., and Dumesnil J.G. Rationale, design, and baseline characteristics of a randomized trial to assess the effect of cholesterol lowering on the progression of aortic stenosis: the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) trial. Am Heart J 153 (2007) 925-931
7. Rossebø A.B., Pedersen T.R., Allen C., Boman K., Chambers J., Egstrup K., Gerdts E., Gohlke-Barwolf C., Holme I., Kesaniemi V.A., et al. Design and baseline characteristics of the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study. Am J Cardiol 99 (2007) 970-973
8. Pohle K., Maffert R., Ropers D., Moshage W., Stilianakis N., Daniel W.G., and Achenbach S. Progression of aortic valve calcification: association with coronary atherosclerosis and cardiovascular risk factors. Circulation 104 (2001) 1927-1932
9. Aronow W.S., Ahn C., Kronzon I., and Goldman M.E. Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am J Cardiol 88 (2001) 693-695
10. Shavelle D.M., Takasu J., Budoff M.J., Mao S., Zhao X.Q., and O'Brien K.D. HMG CoA reductase inhibitor (statin) and aortic valve calcium. Lancet 359 (2002) 1125-1126
11. Rosenhek R., Rader F., Loho N., Gabriel H., Heger M., Klaar U., Schemper M., Binder P., Maurer G., and Baumgartner H. Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation 110 (2004) 1291-1295
12. Bellamy M.F., Pellikka P.A., Klarich K.W., Tajik A.J., and Enriquez-Sarano M. Association of cholesterol levels, hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment, and progression of aortic stenosis in the community. J Am Coll Cardiol 40 (2002) 1723-1730
13. Waters D.D., Guyton J.R., Herrington D.M., McGowan M.P., Wenger N.K., and Shear C. Treating to New Targets (TNT) study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?. Am J Cardiol 93 (2004) 154-158
14. LaRosa J.C., Grundy S.M., Waters D.D., Shear C., Barter P., Fruchart J.C., Gotto A.M., Greten H., Kastelein J.J., Shepherd J., and Wenger N.K. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435
15. Cannon C.P., Braunwald E., McCabe C.H., Rader D.J., Rouleau J.L., Belder R., Joyal S.V., Hill K.A., Pfeffer M.A., and Skene A.M. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
16. Colhoun H.M., Betteridge D.J., Durrington P.N., Hitman G.A., Neil H.A., Livingstone S.J., Thomason M.J., Mackne M.I., Charlton-Menys V., and Fuller J.H. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-696
17. Shepherd J., Blauw G.J., Murphy M.B., Bollen E.L., Buckley B.M., Cobbe S.M., Ford I., Gaw A., Hyland M., Jukema J.W., et al. Pravastatin in Elderly Individuals at Risk of Vascular Disease (PROSPER): a randomised controlled trial. Lancet 360 (2002) 1623-1630
18. Shepherd J., Blauw G.J., Murphy M.B., Cobbe S.M., Bollen E.L., Buckley B.M., Ford I., Jukema J.W., Hyland M., Gaw A., et al., PROSPER Study Group. The design of a prospective study of pravastatin in the elderly at risk (PROSPER). Am J Cardiol 84 (1999) 1192-1197
19. Nissen S.E., Tuzcu E.M., Schoenhagen P., Brown B.G., Ganz P., Vogel R.A., Crowe T., Howard G., Cooper C.J., Brodie B., et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291 (2004) 1071-1080
20. Sever P.S., Dahlof B., Poulter N.R., Wedel H., Beevers G., Caulfield M., Collins R., Kjeldsen S.E., Kristinsson A., McInnes G.T., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361 (2003) 1149-1158
21. MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience. Eur Heart J 20 (1999) 725-741
22. Collins R., Armitage J., Parish S., Sleigh P., and Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361 (2003) 2005-2016
23. Randomized Study to Evaluate the Efficacy of Fluvastatin on Inflammatory Markers in the Haemodynamic Progression of Degenerative Aortic Stenosis. ClinicalTrials.gov. http://www.clinicaltrials.gov/ct2/show/NCT00404287?term=aortic+stenosis&rank=2 Accessed February 2 2008
24. Statin Therapy in Asymptomatic Aortic Stenosis. ClinicalTrials.gov. http://www.clinicaltrials.gov/ct2/show/NCT00176410?term=aortic+stenosis&rank=6 Accessed February 2 2008
25. The Effect of Lipitor on Aortic Stenosis. ClinicalTrials.gov. http://www.clinicaltrials.gov/ct2/show/NCT00590135?term=cleveland+aortic +stenosis&rank=1 Accessed February 2 2008